HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Körbling, M. Articles by Champlin, R. Search for Related Content PubMed PubMed Citation Articles by Körbling, M. Articles by Champlin, R.

Peripheral Blood Progenitor Cell Transplantation: A Replacement for Marrow Auto- or Allografts

University of Texas MD Anderson Cancer Center, Division of Medicine, Department of Hematology, Section of Blood and Marrow Transplantation, Houston, Texas, USA

Key Words. CD34⁺ • Blood stem cells • Apheresis • Autologous stem cell transplantation • Allogenic stem cell transplantation • Hematologic malignancies • Breast/ovarian cancer • Stem cell mobilization • Gene therapy

Dr. Martin Körbling, University of Texas MD Anderson Cancer Center, Division of Medicine, Department of Hematology, Section of Blood & Marrow Transplantation, Box 68, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Circulating hematopoietic progenitor cells include pluripotent stem cells expressing indefinite self-renewal capacity and, therefore, can be used for restoring hematopoiesis following myeloablative treatment. A transient shifting of progenitor cells from extravascular sites into the circulation by chemopriming and/or cytokine treatment enables the collection by apheresis of a sufficient number of progenitor cells to guarantee engraftment. The addition of new cytokines (e.g., thrombopoietin) and large volume apheresis will increase peripheral blood progenitor cell (PBPC) procurement efficiency, whereas the risk of concurrently mobilizing clonogenic tumor cells in patients with solid tumors and hematologic malignancies remains to be carefully evaluated. As compared with bone marrow (BM) progenitor cells, the use of PBPCs significantly shortens the recovery of WBC and platelets following transplantation. Most recently, successful allogeneic transplantation of PBPCs has been reported without increasing the incidence and severity of acute graft-versus-host-disease. Due to the more than one log higher number of lymphoid subsets contained in a PBPC allograft, one might expect a more pronounced graft-versus-leukemia effect in the transplant patient. Similar to BM cells, ex vivo manipulation of mobilized apheresis products is used or being developed (ultralight density percoll gradient, CD8 depletion, selection of graft facilitating cells, CD34⁺ cell purification and others). The transduction and long-term expression of marker genes and, most recently, therapeutic genes (e.g., MDR–1) in PBPCs have been successfully demonstrated by several groups in patients with hematologic malignancies and selected solid tumors. It is expected that, based on the easier procurement of hematopoietic stem cells and advantageous engraftment characteristics, PBPCs in both autologous and allogeneic transplant situations will eventually replace BM-derived progenitor cells.

This article has been cited by other articles:

				N. Russell, R. Mesters, J. Schubert, M. Boogaerts, H. E. Johnsen, C. d. Canizo, N. Baker, P. Barker, T. Skacel, and N. Schmitz A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy Haematologica, March 1, 2008; 93(3): 405 - 412. [Abstract] [Full Text] [PDF]

				G. Ferrandina, L. Pierelli, A. Perillo, S. Rutella, M. Ludovisi, G. Leone, S. Mancuso, and G. Scambia Lymphocyte Recovery in Advanced Ovarian Cancer Patients after High-Dose Chemotherapy and Peripheral Blood Stem Cell Plus Growth Factor Support: Clinical Implications Clin. Cancer Res., January 1, 2003; 9(1): 195 - 200. [Abstract] [Full Text] [PDF]

				S. J. Szilvassy, T. E. Meyerrose, P. L. Ragland, and B. Grimes Differential homing and engraftment properties of hematopoietic progenitor cells from murine bone marrow, mobilized peripheral blood, and fetal liver Blood, October 1, 2001; 98(7): 2108 - 2115. [Abstract] [Full Text] [PDF]

				S. J. Szilvassy, T. E. Meyerrose, and B. Grimes Effects of cell cycle activation on the short-term engraftment properties of ex vivo expanded murine hematopoietic cells Blood, May 1, 2000; 95(9): 2829 - 2837. [Abstract] [Full Text] [PDF]